|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences,_Inc.
gptkb:Gilead_Sciences
gptkb:tenofovir
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
treatment-naive patients
first-line therapy
treatment-experienced patients
|
|
gptkbp:contains
|
gptkb:tenofovir_alafenamide
gptkb:emtricitabine
bictegravir
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to components
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:effective_date
|
gptkb:2018
|
|
gptkbp:formulation
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biktarvy
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:ingredients
|
gptkb:tenofovir_alafenamide
gptkb:emtricitabine
bictegravir
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:rifampin
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
viral suppression
immune recovery
|
|
gptkbp:is_used_for
|
treatment of HIV
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketed_as
|
gptkb:Biktarvy
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:pharmacokinetics
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
integrase strand transfer inhibitor
nucleotide reverse transcriptase inhibitor
high bioavailability
once daily dosing
|
|
gptkbp:population
|
adults
pediatric patients over 12 years
|
|
gptkbp:previous_name
|
gptkb:theorem
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
once daily
WHO guidelines
CDC guidelines
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:safety_features
|
liver function tests
renal function tests
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
|
|
gptkbp:storage
|
room temperature
|